Imaging CRO Upsell Qureight offers end-to-end imaging CRO capabilities with AI-powered data curation and automated image management, presenting a sales opportunity to expand into biopharmaceutical clients needing scalable imaging endpoints and faster trial timelines.

Lung Disease Focus Specialization in Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Bronchiectasis, and Pulmonary Hypertension aligns with high-need therapeutic areas, suggesting cross-sell potential with sponsors targeting respiratory indications and new IPF/IPF-related programs.

Recent Growth Series B funding and board additions indicate rapid scale and maturity, signaling readiness for larger multi-center trials and partnerships, with credibility to pursue tier-one biopharma collaborations.

Strategic Partnerships Active collaborations and participation in major conferences (ERS Congress) show momentum in scientific validation and visibility, offering entry points for co-development pilots and joint abstracts with potential clients.

Technology Enablement Tech stack emphasizing cloud-based analytics, AI-enabled imaging, and scalable data curation positions Qureight as a platform to replace legacy imaging workflows, enabling sales pitches around improved data quality, faster endpoints, and regulatory-grade outputs.